Tourette’s Syndrome

  • Kirsten R. Müller-VahlEmail author
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 1)


Tourette’s syndrome (TS) is a chronic disorder characterized by motor and vocal tics and a variety of associated behaviour disorders. Because current therapy is often unsatisfactory, there is expanding interest in new therapeutic strategies that are more effective, cause less side effects and ameliorate not only tics but also behavioural problems. From anecdotal reports and preliminary controlled studies it is suggested that – at least in a subgroup of patients – cannabinoids are effective in the treatment of TS. While most patients report beneficial effects when smoking marijuana (Cannabis sativa L.), available clinical trials have been performed using oral Δ9-tetrahydrocannabinol (THC). In otherwise treatment-resistant TS patients, therefore, therapy with THC should not be left unattempted. To date, it is unknown whether other drugs that interact with the endocannabinoid receptor system might be more effective in the treatment of TS than smoked marijuana or pure THC. Since it has been suggested that abnormalities within the endocannabinoid receptor system might underlie TS pathophysiology, it would be of interest to investigate the effect of substances that for example bind more selectively to the central cannabinoid receptor or inhibit the uptake or the degradation of different endocannabinoids.


Tourette’s syndrome Tic Attention obsessive compulsive disorder OCD 





Attention deficit hyperactivity disorder


Global clinical impression scale


Globus pallidus


Magnetic resonance imaging




Parkinson's disease


Positron emission tomography


Obsessive compulsive behaviour


Single-strand conformation polymorphism


Selective serotonin-reuptake inhibitors


Shapiro Tourette-syndrome severity scale


Tourette’s syndrome


Tourette’s syndrome global scale


Tourette syndrome symptom list


Yale global tic severity scale


  1. Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097–2102PubMedCrossRefGoogle Scholar
  2. Adriani W, Caprioli A, Granstrem O et al. (2003) The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 2:639–651CrossRefGoogle Scholar
  3. Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119–146PubMedCrossRefGoogle Scholar
  4. Benton AL (1945) A visual retention test for clinical use. Arch Neurol Psychol 59:273–291Google Scholar
  5. Berding G, Müller-Vahl K, Schneider U et al. (2004) [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 55:904–915PubMedCrossRefGoogle Scholar
  6. Block RI, Ghoneim MM (1993) Effects of chronic marijuana use on human cognition. Psychopharmacology (Berl) 110:219–228CrossRefGoogle Scholar
  7. Cadogan AK, Alexander SP, Boyd EA et al. (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131–1137PubMedCrossRefGoogle Scholar
  8. Derogatis LR (1977) SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of MedicineGoogle Scholar
  9. Derogatis LR, Lipman RS, Covi L (1973) SCL-90: an outpatient psychiatric rating scale–preliminary report. Psychopharmacol Bull 9:13–28PubMedGoogle Scholar
  10. Di Marzo V, Hill MP, Bisogno T et al. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432–1438PubMedCrossRefGoogle Scholar
  11. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15–21PubMedGoogle Scholar
  12. Gadzicki D, Müller-Vahl KR, Heller D et al. (2004) Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet 127:97–103CrossRefGoogle Scholar
  13. Gerard E, Peterson BS (2003) Developmental processes and brain imaging studies in Tourette syndrome. J Psychosom Res 55:13–22PubMedCrossRefGoogle Scholar
  14. Gessa GL, Melis M, Muntoni AL et al. (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39–44PubMedCrossRefGoogle Scholar
  15. Giuffrida A, Parsons LH, Kerr TM et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363PubMedCrossRefGoogle Scholar
  16. Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299–318PubMedCrossRefGoogle Scholar
  17. Goetz CG, Tanner CM, Wilson RS et al. (1987) A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 37:1542–1544PubMedGoogle Scholar
  18. Harcherik DF, Leckman JF, Detlor J et al. (1984) A new instrument for clinical studies of Tourette’s syndrome. Am J Acad Child Psychiatry 23:153–160CrossRefGoogle Scholar
  19. Helmstaedter C, Durwen HF (1990) VLMT. Verbaler Lern- und Merkfähigkeitstest. Schweiz Arch Neurol Psychiatr 141:21–30PubMedGoogle Scholar
  20. Hemming M, Yellowlees PM (1993) Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 7:389–391CrossRefGoogle Scholar
  21. Herkenham M, Lynn AB, Little MD et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936PubMedCrossRefGoogle Scholar
  22. Leckman JF, Towbin KE, Ort SI et al. (1988) Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF (eds) Tourette’s syndrome and tic disorders. Wiley, New YorkGoogle Scholar
  23. Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705–1712PubMedCrossRefGoogle Scholar
  24. Mantel BJ, Meyers A, Tran QY et al. (2004) Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol 14:582–589PubMedCrossRefGoogle Scholar
  25. Merz J, Lehrl S, Galster JV et al. (1975) MWT-B – ein Intelligenzkurztest. Psychiatr Neurol Med Psychol 27:423–428Google Scholar
  26. Mink JM (2001) Neurobiology of basal ganglia circuit in Tourette Syndrome: faulty inhibition of unwanted motor patterns? Adv Neurol 85:113–122PubMedGoogle Scholar
  27. Moss DE, Montgomery SP, Salo AA et al. (1984) Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson’s disease. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Academic Press, New YorkGoogle Scholar
  28. Moss DE, Manderscheid PZ, Montgomery SP et al. (1989) Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 44:1521–1525PubMedCrossRefGoogle Scholar
  29. Müller-Vahl KR (2002) The treatment of Tourette’s syndrome: current opinions. Expert Opin Pharmacother 3:899–914PubMedCrossRefGoogle Scholar
  30. Müller-Vahl KR (2006) Involvement of fronto-striatal pathways in Tourette syndrome with and without comorbid ADHD and OCD. Eur Arch Psychiatry Clin Neurosci 256:II19Google Scholar
  31. Müller-Vahl KR, Kolbe H, Dengler R (1997a) Alcohol withdrawal and Tourette’s syndrome. Neurology 48:1478–1479PubMedGoogle Scholar
  32. Müller-Vahl KR, Kolbe H, Dengler R (1997b) Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms. Nervenarzt 68:985–989PubMedCrossRefGoogle Scholar
  33. Müller-Vahl KR, Kolbe H, Schneider U et al. (1998) Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand 98:502–506PubMedCrossRefGoogle Scholar
  34. Müller-Vahl KR, Schneider U, Kolbe H et al. (1999) Treatment of Tourette-syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry 156:395Google Scholar
  35. Müller-Vahl KR, Koblenz A, Jobges M et al. (2001) Influence of delta-9-Tetrahydrocannabinol (Δ9-THC) treatment of Tourette-syndrome on neuropsychological testing. Pharmacopsychiatry 34:19–24PubMedCrossRefGoogle Scholar
  36. Müller-Vahl KR, Schneider U, Emrich HM (2002a) Combined treatment of Tourette-syndrome with Δ9-THC and dopamine receptor antagonists. J Cannabis Ther 2:145–154Google Scholar
  37. Müller-Vahl KR, Schneider U, Koblenz A et al. (2002b) Treatment of Tourette-syndrome with Δ9-Tetrahydrocannabinol (THC). Pharmacopsychiatry 35:57–61PubMedCrossRefGoogle Scholar
  38. Müller-Vahl KR, Prevedel H, Theloe K et al. (2003a) Treatment of Tourette-syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384–388PubMedCrossRefGoogle Scholar
  39. Müller-Vahl KR, Schneider U, Prevedel H et al. (2003b) Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette-Syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459–465PubMedCrossRefGoogle Scholar
  40. Müller-Vahl KR, Buddensiek N, Geomelas M et al. (2008) The influence of different food and drink on tics in Tourette syndrome. Acta Paediatr 97:442–446PubMedCrossRefGoogle Scholar
  41. Patton GC, Coffey C, Carlin JB et al. (2002) Cannabis use and mental health in young people: cohort study. BMJ 325:1195–1198PubMedCrossRefGoogle Scholar
  42. Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123:425–462PubMedCrossRefGoogle Scholar
  43. Sandyk R, Awerbuch G (1988) Marijuana and Tourette’s syndrome. J Clin Psychopharmacol 8:444–445PubMedCrossRefGoogle Scholar
  44. Shapiro AK, Shapiro ES, Young JG et al. (1988) Signs, symptoms, and clinical course. In: Shapiro AK, Shapiro ES, Young JG, Feinberg TE (eds) Gilles de la Tourette syndrome, 2nd edn. Raven Press, New YorkGoogle Scholar
  45. Sieradzan KA, Fox SH, Hill M et al. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108–2111PubMedGoogle Scholar
  46. Singer HS (2000) Current issues in Tourette syndrome. Mov Disord 15:1051–1063PubMedCrossRefGoogle Scholar
  47. Singer HS, Wendtlandt JT (2001) Neurochemistry and synaptic neurotransmission in Tourette syndrome. Adv Neurol 85:163–178PubMedGoogle Scholar
  48. Solowij N, Michie PT, Fox AM (1995) Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37:731–739PubMedCrossRefGoogle Scholar
  49. Strohbeck-Kühner P, Skopp G, Mattern R (2007) Fitness to drive in spite (because) of THC. Arch Kriminol 220:11–19PubMedGoogle Scholar
  50. The Tourette syndrome classification study group (1993) Definitions and classification of tic disorders. Arch Neurol 50:1013–1016Google Scholar
  51. Tzavara ET, Li DL, Moutsimilli L et al. (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry 59:508–515PubMedCrossRefGoogle Scholar
  52. Zimmermann P, Fimm B (1989) Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität FreiburgGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Clinic of Psychiatry, Social Psychiatry and PsychotherapyHannover Medical SchoolHannoverGermany

Personalised recommendations